New first-in-class phase 3 data demonstrate tremfya®▼ (guselkumab) maintained skin clearance rates through nearly 5 years of continuous use in adult patients with moderate to severe plaque psoriasis

The janssen pharmaceutical companies of johnson & johnson today announced new open-label extension data from the phase 3 voyage 1 study, which sho

HOFV Ratings Summary

HOFV Quant Ranking